FDA Memo Suggests Possible Link Between COVID Vaccines and 10 Child Deaths — 29 November 2025

US FDA Memo Suggests Possible Link Between COVID Vaccines and 10 Child Deaths — 29 November 2025

A recently exposed internal memo from the U.S. Food and Drug Administration (FDA) has raised serious concern by suggesting that at least 10 children may have died as a result of COVID‑19 vaccination. The memo reportedly describes the circumstances as “a profound revelation” and cites myocarditis — inflammation of the heart — as a potential contributing cause to the fatalities.

The memo claims the child deaths occurred “after and because of” COVID vaccinations. However, crucial details are missing. The memo does not disclose the children’s ages, their prior health conditions or medical histories, nor does it name which vaccine manufacturers produced the shots in question.

Moreover, the document has not been publicly released or published in any peer‑reviewed medical journal, which is an important step for independent scientific scrutiny. This lack of transparency and absence of key data means that, while the memo expresses a serious concern, these findings remain preliminary and unconfirmed.

In response to the memo, the FDA appears poised to reconsider its vaccine approval and monitoring processes. The report signals that the agency may impose stricter oversight, including requirements for randomized clinical trials across all subgroups — including children — before approving future vaccines. Meanwhile, the U.S. Department of Health and Human Services has reportedly adjusted vaccine policy, limiting COVID‑19 vaccination eligibility to individuals aged 65 and above or those with underlying health conditions.

Public health experts and several scientists are urging caution. Critics emphasize that an internal memo — without peer‑review or full data disclosure — cannot be taken as definitive evidence of causality. What the memo highlights, they say, is a safety signal that warrants detailed investigation, transparent data release, and independent review. Until then, conclusions should remain tentative.

Importantly, the broader context must not be ignored. Since the start of the pandemic, COVID‑19 vaccines have been credited with averting large numbers of hospitalizations, severe illnesses, and deaths worldwide. While rare adverse events can occur, public‑health authorities have maintained that the benefits of mass vaccination — especially among high‑risk groups — far outweighed potential risks. This remains a cornerstone of vaccine policy and public-health strategy.

At present, parents, healthcare professionals, and policymakers are demanding greater transparency from regulatory agencies: release of full data, details on the 10 deaths (ages, underlying conditions, timing), and independent scientific evaluation. Many also call for strengthened post‑vaccination monitoring systems and stricter clinical‑trial requirements before authorizing future vaccines for children.

As the situation unfolds, the FDA and other U.S. public‑health bodies including the Centers for Disease Control and Prevention (CDC) are expected to convene in coming weeks to review this revelation and potentially update vaccine guidelines. Until then, this memo remains a warning sign — a call for transparency, caution, and scientific rigor — not conclusive proof.